1034191-62-2

Upstream product

• 13734-41-3 t-Boc-L-valine 
• 380306-30-9 1-O-(tert-butyldimethylsilyl)-3-[2-(N-Boc-L-valyloxy)-4,6-dimethylphenyl]-3,3-dimethylpropan-1-ol 
• 134098-64-9 2‐{3‐[(O‐tert‐butyldimethylsilyl)hydroxy]‐1,1‐dimethylpropyl}‐3,5‐dimethylphenol 
• 1034191-61-1 2-tert-butoxycarbonylamino-3-methyl-butyric acid 2-(3-hydroxy-1,1-dimethyl-propyl)-3,5-dimethyl-phenyl ester 

Downstream Products

• 1034191-48-4 C₂₁H₃₄N₂O₆S 
• 1034191-63-3 C₂₆H₄₂N₂O₈S 

Relevant academic research and scientific papers

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Coumarin derivatives as protease-sensitive prodrugs

To overcome the lack of selectivity of anticancer drugs toward malignant cells, the development of prodrugs, which could be activated selectively by tumour-specific proteases is the goal of these studies. In this work tripartate prodrugs have been evaluated consisting of a carrier unit and a spacer group, which allows for intramolecular cyclisation while releasing the third component, the compound attached to the carboxylic acid moiety of the spacer group. As carrier units amino acids or peptides have been used, which are required for recognition by the protease. As the spacer unit the "trimethyl-lock"-spacer has been applied; as a model leaving group p-anisidine was attached to the carboxylic acid moiety. It was intended to test the compounds for their releasing rate of p-anisidine. Two of the evaluated compounds, 9b and 9h, were degraded with half-lives of 46 min at room temperature. However, the poor solubility in aqueous solutions proved the major disadvantage of the TML-based prodrugs.